Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: A retrospective cohort study

HIV Medicine

Volumn 6, Issue 2, 2005, Pages 79-90

  Richter, Anke ^a   Pladevall, M ^b   Manjunath, R ^c   Lafata, J E ^b   Xi, H ^b   Simpkins, J ^b   Brar, I ^d   Markowitz, N ^d   Iloeje, U H ^e   Irish, W ^c  

^a NAVAL POSTGRADUATE SCHOOL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

^d Henry Ford Health System Division of Infectious Diseases   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Costs; Disease burden; Dyslipidaemia; HAART; HIV; Medical resource use

Indexed keywords

ANTIRETROVIRUS AGENT; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; AUTOMATION; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG COST; DYSLIPIDEMIA; FACTUAL DATABASE; FEMALE; HEALTH CARE COST; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC DISORDER; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; RESOURCE MANAGEMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL;

ADULT; AGE FACTORS; ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DRUG COSTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 20144366551     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00269.x     Document Type: Article

References (37)

1. Segarra-Newnham M. Hyperlipidemia in HIV-positive patients receiving antiretrovirals. Ann Pharmacother 2002; 36: 592-595.
2. Friis-Moller N, Reiss P, Kirk O et al. Cardiovascular risk factors in HIV patients. Association with antiretroviral therapy. The DAD Study. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece, October 2001 [Abstract 018].
3. Lichtenstein KA, Ward DJ, Moorman A et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15: 1389-1398.
4. Martinez E, Mocroft A, Garcia-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592-598.
5. Heath KV, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15: 231-239.
6. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. J Am Med Assoc 2000; 284: 472-477.
7. Polo R, Verdejo J, Gonzalez-Munoz M et al. Lipodystrophy related to NRT inhibitors in HAART therapy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, 27 September 1999 [Abstract 1302].
8. Madge S, Kinloch DE, Loes K, Mercey D, Johnson MA, Weller IVD. Lipodystrophy in patients naïve to HIV protease inhibitors. AIDS 1999; 13: 735-737.
9. Galli M, Ridolfo AL, Gervasoni C et al. Incidence of fat tissue abnormalities in patients treated with nucleoside reverse transcriptase inhibitors. 7th International Conference on the Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 1999 [Abstract].
10. Aldeen T, Wells C, Hay P, Davidson F, Lau R. Lipodystrophy associated with nevirapine-containing antiretroviral therapies. AIDS 1999; 13: 865-867.
11. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932-1937.
12. Shikuma C, Waslien C, McKeague J et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999; 13: 1359-1365.
13. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
14. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 2050-2056.
15. van der Valk M, Gisolf EH, Reiss P et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 2001; 15: 847-855.
16. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc 2003; 289: 2978-2982.
17. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JSG, Hogg RS. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002; 31: 1016-1020.
18. Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy. Arch Intern Med 2002; 162: 2621-2628.
19. Thiebaut R, Daucourt V, Mercie P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000; 31: 1482-1487.
20. Kotler DP, Rosenbaum KB, Wang J, Peirson RN Jr. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999; 20: 228-237.
21. Shaw AJ, McLean KA, Evans BA. Disorders of fat redistribution in HIV infection. Int J STD AIDS 1998; 9: 595-599.
22. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.
23. Sattler FR, Qian D, Louie S et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15: 2001-2010.
24. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Eng J Med 2003; 348: 702-710.
25. Holmberg SO, Moorman AC, Williamson JM et al. and the HIV Outpatient Study (HOPS) investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360 1747-1748.
26. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Eng J Med 2003; 349: 1993-2003.
27. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
28. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002; 106: 3143-3421.
29. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
30. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5: 329-333.
31. American Diabetes Association National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27.
32. Duong M, Petit JM, Piroth L et al. Between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus co-infected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-250.
33. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active antiretroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731-736.
34. Grumfeld CP. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003; 37: 543-546.
35. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961-1976.
36. Dube MP, Stein JH, Aberg JA et al. for the Adult AIDS, Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-627.
37. The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr 2002; 30: 21-26.